Pearl Pathways hires three new associates

The diverse backgrounds of our new teammates serve growing demands of Pearl Pathways’ clients. FOR IMMEDIATE RELEASE INDIANAPOLIS, INDIANA –February 25, 2013- Pearl Pathways announces the recent hiring of Daphine Glowner, Gretchen Parker, PhD, RAC and Sarah...

FDA emphasizes the crucial role of IRBs in new draft guidelines

The new FDA draft guidance issued last during the second week of November demonstrates that FDA does not want institutional review boards (IRBs) to lose their critical role in the clinical research process.  The new guidance, issued in November 2012 entitled “IRB...

Supplementary data research causing unnecessary expenditures

Ken Getz, assistant professor at Tufts Center for the Study of Drug Development (CSDD), reports that oftentimes procedures performed in the last drug development stages are in order to find “supplementary, secondary, tertiary, and exploratory endpoints.”...

Pearl Hires J. Ellen Looney as IRB Administrator

Pearl Pathways is excited to announce the recent hiring of J. Ellen Looney as an IRB administrator.  Ellen is well experienced and has Pearl Pathways CEO, Diana Caldwell, excited to have her as part of the Pearl team, “Our staff and clients are lucky to have Ellen...